AbbVie Q2 Revenue Seen Up 8.8%; US Probes China Trial Data
ABBV sits 40% above its 52-week low of $187.62.
Summary
Analysts expect AbbVie's Q2 revenue to rise 8.8% year-over-year, an acceleration from last year's 6.6% growth, signaling continued top-line momentum ahead of the earnings release. Separately, U.S. lawmakers are demanding details on data protection and oversight of AbbVie's clinical trials in China, specifically at Xinjiang and military-linked hospitals — a new regulatory risk that could affect its extensive China operations. This follows a strong Q1 with 12.4% revenue growth and the $10.9B Apogee Therapeutics acquisition announced in June. The China inquiry introduces geopolitical uncertainty that traders will weigh against the upbeat revenue forecast.
At the time of this announcement, ABBV was trading at $263.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $465.2B. The 52-week trading range was $187.62 to $267.47. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.